DekaBank Deutsche Girozentrale Lowers Position in Zoetis Inc. $ZTS

DekaBank Deutsche Girozentrale lessened its position in Zoetis Inc. (NYSE:ZTS) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 332,878 shares of the company’s stock after selling 37,544 shares during the period. DekaBank Deutsche Girozentrale owned about 0.07% of Zoetis worth $52,371,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC raised its position in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp boosted its stake in shares of Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its stake in shares of Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after purchasing an additional 312,746 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 0.7%

NYSE ZTS opened at $146.13 on Wednesday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $189.98. The company’s 50-day moving average price is $148.58 and its 200-day moving average price is $153.55. The stock has a market cap of $64.76 billion, a PE ratio of 25.15, a PEG ratio of 2.33 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio is 34.42%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Argus restated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $195.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.